Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter

Abcuro, Inc. has come a long way since it raised $42m in series A-1 venture capital at the start of 2021 and it plans to take its lead drug candidate even further with $155m in series B funding that the company announced on 17 August. ABC008 moved through Phase I/II testing in inclusion body myositis (IBM) and into a Phase II/III clinical trial in IBM and now the drug candidate has funding to see it through to the readout of that pivotal study and completion of Phase I/II trials in two additional rare indications.

CEO Alex Martin told Scrip that Abcuro’s series B round will support the company’s operations “well into 2026” without the need to enlist a partner for the development of ABC008 – a killer cell lectin like receptor G1 (KLRG1) inhibitor – in its first three indications of IBM, T-cell